Core Viewpoint - Organigram Global Inc. has received a recommendation from Institutional Shareholder Services Inc. (ISS) for shareholders to vote in favor of the acquisition of Sanity Group GmbH, citing strong strategic rationale and institutional confidence in the transaction [1][3]. Acquisition Details - The acquisition involves a combination of cash and Organigram shares valued at C$3.00 per share for Sanity shareholders, representing a 71.4% premium over the last unaffected trading price [4]. - The total upfront consideration for the acquisition is €113.4 million, consisting of €80.0 million in cash and €33.4 million in Organigram shares, with potential contingent earn-out consideration of up to €113.8 million based on Sanity's financial performance post-closing [4]. Strategic Rationale - ISS highlighted that the acquisition will provide increased scale, geographic diversification, improved market presence, a stronger balance sheet, and enhanced cash flow generation for the combined company [3]. - The transaction is supported by a private placement financing from British American Tobacco, Organigram's largest shareholder, indicating strong institutional confidence [3]. Market Reaction - Following the announcement, Organigram's shares experienced a positive market reaction, outperforming both the S&P/TSX Composite Index and the S&P/TSX Composite Pharmaceuticals Index [10]. - ISS noted that the favorable market reaction suggests elevated risk if the transaction is not approved [10]. Board Support - The Board of Directors of Organigram unanimously recommends that shareholders vote in favor of the transaction, having consulted with financial and legal advisors and received a fairness opinion confirming the financial fairness of the deal [5][10]. Meeting Matters - In addition to the acquisition vote, shareholders will also vote on the election of ten director nominees, the appointment of PricewaterhouseCoopers LLP as auditor, and the re-approval of unallocated awards under the Omnibus Equity Incentive Plan, with the Board recommending support for all these matters [6].

Core Insights - Organigram Global Inc. reported strong year-over-year growth in Q1 Fiscal 2026, driven by Canadian market leadership and increasing international sales, alongside improved gross margins [1][2] Financial Performance - Net revenue increased by 49% to $63.5 million from $42.7 million in Q1 Fiscal 2025, primarily due to contributions from the Motif Labs acquisition and higher international sales [1][2] - Adjusted gross margin rose to $23.9 million, or 38% of net revenue, compared to $14.3 million, or 33%, in Q1 Fiscal 2025, attributed to operational efficiencies and higher flower yields [1][2] - Adjusted EBITDA reached $5.3 million, a 273% increase year-over-year, driven by higher recreational and international revenue [1][2] Operational Highlights - The company harvested 28,645 kilograms, a 43% increase compared to Q1 Fiscal 2025, achieved through nutrient and environmental enhancements [1] - Organigram launched its Collective Project and Fetch brands into Illinois and Wisconsin, expanding its U.S. retail footprint to 11 states [1] - The company achieved a proprietary genetic screening breakthrough for powdery mildew resistance, significantly reducing identification time [1] Market Position - Organigram holds the 1 market share in Canada for vapes, milled flower, and concentrates, and ranks 2 in pre-rolls and 3 in edibles and dried flower [1] - International sales reached $5.0 million, a 51% increase year-over-year, with expectations for continued growth [1][2] Balance Sheet and Liquidity - As of December 31, 2025, the company had total cash of $63.0 million, with total assets amounting to $530.7 million [2] - Total liabilities decreased by 24% to $161.2 million, while shareholders' equity increased by 6% to $369.5 million [2]